Kaneka Completes Construction of Medical Device Plant in Hokkaido
30.8.2024 08:34:00 EEST | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido for the purpose of portfolio transformation and business expansion and held the opening ceremony on August 26. The Tomatoh Manufacturing Site is the seventh domestic business location*1 for the company and the first new one in 54 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829240050/en/
Tomatoh Manufacturing Site (Photo: Business Wire)
The medical device plant*2 completed at Tomatoh Manufacturing Site will produce adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™". The number of patients with arteriosclerosis obliterans (ASO)*3, which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. By securing the supply base through the new plant, we will dramatically expand our medical business to meet global demand.
The plant has achieved full automation of its production lines as a "smart factory" utilizing robot technology and plans to realize a "zero energy factory" that will reduce the primary energy consumption of the factory building to zero by using our photovoltaic modules, thereby promoting sustainable manufacturing.
In the future, Tomatoh Manufacturing Site will be actively utilized as a new production base for each business, as well as for further expansion of the medical business.
Based on our mission of "KANEKA thinks 'Wellness First'.", we will realize a world where advanced medical care is accessible to everyone and where science contributes to the innovation of the global environment and our daily lives. From Tomakomai, "Kaneka, the Dream Factory" will make this vision a reality.
Participants at the opening ceremony (From the left):
Yoshiro Aikawa, President of Taisei Corporation
Jun Kimura, Deputy Mayor of Tomakomai-city
Naomichi Suzuki, Governor of Hokkaido
Kimikazu Sugawara, Chairman of Kaneka Corporation
Kazuhiko Fujii, President of Kaneka Corporation
Shigenobu Sano, Senior Executive Director of Tomatoh Co., Ltd.
*1. Domestic business locations: Takasago Manufacturing Site, Osaka Manufacturing Site, Shiga Manufacturing Site, Kashima Manufacturing Site, Tomatoh Manufacturing Site, Tokyo Head Office, Osaka Head Office
*2. News Release January 23, 2022
Kaneka to Construct New Medical Device Plant in Hokkaido - Roughly 10 billion yen investment aimed at expanding global business -
https://www.kaneka.co.jp/en/topics/news/2022/ennr2201241.html
*3. A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia). In the early stages, it causes coldness, numbness, and gait disturbance. When the disease progresses to critical limb ischemia with pain and ulceration, the risk of leg amputation and death increases.
About Tomatoh Manufacturing Site
Company Name: Kaneka Corporation Tomatoh Manufacturing Site
Completed: August 26, 2024
Location: 6-253 Kashiwabara, Tomakomai-city, Hokkaido
Business Description: Production of medical devices
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829240050/en/
Contacts
KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 20:01:00 EEST | Press release
TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet365 can lead with technical excellence by testing on real-world configurations that mirror its diverse global user base. Founded in 20
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 17:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application and scale, we are well-positioned to help our customers translate th
Andersen Consulting Strengthens Capabilities with Addition of Lukkap31.3.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm Lukkap, a consultancy focused on experience-driven capabilities aligned with clients’ evolving people, customer, and digital transformation needs. Founded in 2009 and headquartered in Spain, Lukkap delivers integrated solutions that help organizations transform how they serve customers, engage employees, and unlock value through behavioral insights and data analytics. The firm’s multidisciplinary approach spans customer journey redesign, high-impact employee experience programs, talent and leadership development, predictive analytics, and comprehensive outplacement and transition services. Lukkap works across sectors — including healthcare, pharmaceutical, consumer goods, retail, finance, and banking — to build human-centered strategies that drive measurable business results. “By combining our experience-led methodology with Andersen Consulting’s global platform, we can accelerate the way organizations approach customer experience,” said Albe
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 16:26:00 EEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 16:25:00 EEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom